Tofacitinib Acid Impurity
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

2328165-36-0Tofacitinib Acid Impurity

● In Stock

Catalogue No.:VE008140
CAS No.:2328165-36-0
Mol. Formula:C16H21N5O3
Mol. Weight:331.37 g/mol

Additional information on CAS 2328165-36-0

Parent drug

Tofacitinib

IUPAC Name

3-((3R, 4R)-4-Methyl-3-(methyl(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoic Acid

Pharmacopoeial Synonyms

N/A

Other Synonyms

Tofacitinib Inhouse Impurity K

Smiles

O=C(O)CC(N1C[C@H](N(C)C2=C3C(NC=C3)=NC=N2)[C@H](C)CC1)=O

InChI

InChI=1S/C16H21N5O3/c1-10-4-6-21(13(22)7-14(23)24)8-12(10)20(2)16-11-3-5-17-15(11)18-9-19-16/h3,5,9-10,12H,4,6-8H2,1-2H3,(H,23,24)(H,17,18,19)/t10-,12+/m1/s1

Description

Tofacitinib Acid Impurity, also known as Tofacitinib Inhouse Impurity K is a highly characterized reference material. It fully complies with stringent regulatory standards, including those set by USP, EMA, JP, and BP. This product is essential for use in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial production of. Tofacitinib Moreover, it comes with a detailed Structure Elucidation Report (SER), ensuring its accuracy and reliability for a wide range of analytical applications.” Tofacitinib Acid Impurity (CAS No: 2328165-36-0) Or 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoic Acid, Tofacitinib Acid is an Impurity Tofacitinib, Tofacitinib is Janus kinase inhibitor, used in the treatment of renal transplantation, rheumatoid arthritis, psoriasis, and ulcerative colitis.

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url